Related Experiment Video
Updated: Aug 25, 2026

Measurements of Motor Function and Other Clinical Outcome Parameters in Ambulant Children with Duchenne Muscular Dystrophy
Published on: January 12, 2019
[Management of patients with Duchenne muscular dystrophy]
1Department of Neurology, National Hokone Hospital, Odawara, Kanagawa. isiharat@hakone.hosp.go.jp
Abstract:
As there is no cure in Duchenne muscular dystrophy (DMD), we must pay attention to the management of its cardiopulmonary complications. In 1984, DMD patients died at the mean age of 18.2 years in my hospital. From autopsy findings, the cause of death was respiratory failure in 75% of them, and left-sided heart failure 12.5%. First, we had to know the relationship between cardiac and respiratory systems. Based on the findings of right-sided heart catheterization, patients with respiratory failure were classified into Forrester's subset 1' normal left ventricular function. These results showed that these patients require treatment with a respirator, but not with digitalis and/or diuretics. Since 1984, we tried cuirass ventilation, which prolonged their lives by about 3 years. Since 1991, NIPPV was introduced in Japan, and prolonged their lives by about 5.5 years. Nowadays TIPPV with tracheostomy is not the first choice of treatment, but we do not hesitate to select this treatment any more. As for left-sided heart failure, brain natriuretic peptide (BNP) is now considered a useful parameter of left ventricular function. Japanese clinical researcher proposed treatment based on values of BNP in left-sided heart failure. In 1980s, the mean interval from the onset of heart failure to death was only 16 months. Recently we feel that better results have already been accomplished. In 2002 Kawai reported that average age at death in Japan was 26.8 years old. More efforts must be made until cure of this disease is found.
Insights
Management of cardiopulmonary complications in Duchenne muscular dystrophy (DMD) has improved survival. Advances in respiratory support, like NIPPV, have significantly extended lives, offering hope for better outcomes.
Area of Science:
- Neurology
- Cardiology
- Pulmonology
Context:
- Duchenne muscular dystrophy (DMD) is a progressive neuromuscular disorder with no cure.
- Cardiopulmonary complications are the primary cause of mortality in DMD patients.
- Historically, survival was limited, with respiratory failure and heart failure being major concerns.
Purpose:
- To review the evolution of managing cardiopulmonary complications in Duchenne muscular dystrophy.
- To highlight advancements in respiratory support and their impact on patient survival.
- To discuss the role of brain natriuretic peptide (BNP) in managing left-sided heart failure in DMD.
Summary:
- Respiratory failure was the leading cause of death in DMD patients in 1984.
- Introduction of cuirass ventilation and later Non-Invasive Positive Pressure Ventilation (NIPPV) significantly prolonged survival.
- Brain natriuretic peptide (BNP) is a valuable marker for assessing left ventricular function and guiding treatment for heart failure in DMD.
Impact:
- Improved management strategies have increased the average age of death for DMD patients.
- Non-Invasive Positive Pressure Ventilation (NIPPV) has extended survival by approximately 5.5 years.
- Continued research is crucial for developing a cure for Duchenne muscular dystrophy.
Related Concept Videos
Satellite Stem Cells and Muscular Dystrophy
Cardiomyopathy V: Interprofessional Care
Cardiomyopathy II: Dilated Cardiomyopathy
Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Cystic Fibrosis: Management
Sinus disease and chronic sinusitis...
Cardiomyopathy VI: Nursing Management

